Superhumanisation™
Superhumanisation™ compares the structure of the target-binding region of a mouse and a human antibody. It then converts the mouse antibody, which would otherwise be rejected if administered to humans, into a “humanised” form, which can be given safely to patients.By starting with a rodent antibody and “humanising” it, the Superhumanisation™ technology better retains the important properties of the starting antibody. The Superhumanisation™ method, developed by EvoGenix, has delivered quality antibodies with a 100% success rate.
